- Integration of CiNii Books functions for fiscal year 2025 has completed
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on November 26, 2025】Regarding the recording of “Research Data” and “Evidence Data”
- Start the collection of all publicly IRDB content
- Incorporate Research Data from KAKEN
Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer
-
- Seiji Mabuchi
- Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8522, Japan
-
- Tomoyuki Sasano
- Department of Obstetrics and Gynecology, Osaka Saiseikai Nakatsu Hospital, Osaka 530-0012, Japan
-
- Naoko Komura
- Department of Obstetrics and Gynecology, Kaizuka City Hospital, Osaka 597-0015, Japan
Bibliographic Information
- Published
- 2021-02-05
- Resource Type
- journal article
- Rights Information
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.3390/cells10020329
- Publisher
- MDPI AG
Description
<jats:p>Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity. They also directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In ovarian cancer, there are increased numbers of circulating or tumor-infiltrating MDSCs, and increased frequencies of MDSCs are associated with a poor prognosis or an advanced clinical stage. Moreover, in murine models of ovarian cancer, MDSC depletion has shown significant growth-inhibitory effects and enhanced the therapeutic efficacy of existing anticancer therapies. In this review, we summarize the current knowledge on MDSC biology, clinical significance of MDSC, and potential MDSC-targeting strategies in ovarian cancer.</jats:p>
Journal
-
- Cells
-
Cells 10 (2), 329-, 2021-02-05
MDPI AG
